Jul 06, 2019
Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer
Jun 18, 2019
The BRAF kinase inhibitors market will register a CAGR of over 8% by 2023
May 07, 2019
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
Feb 05, 2019
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
Jan 14, 2019
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
Oct 30, 2018
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
Oct 23, 2018
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018
Sep 20, 2018
European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma
Sep 13, 2018
Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
Aug 14, 2018
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
Aug 07, 2018
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018
Jul 27, 2018
BRAFTOVI(TM) (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Jul 13, 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Jun 28, 2018
Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI® (binimetinib)
Apr 30, 2018
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Mar 22, 2018
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
Dec 27, 2017
CStone files MEK inhibitor CS3006 for clinical trial approval in Australia
Dec 22, 2017
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Nov 17, 2017
Melanoma: KOL Insight 2016
Nov 06, 2017
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer